Reivindicaciones

CLAIMS 1 . An intracellular drug delivery composition comprising a particle, said particle comprising one or more active agents and a proteolipid composition, said proteolipid composition consisting of (a) surfactant-protein B (SP-B) and (b) one or more lipids; wherein said particle is not a cationic liposome; and wherein said drug delivery composition does not comprise SP-C. 2. The composition according to claim 1 , wherein the one or more lipids are phospholipids. 3. The composition according to claim 1 or 2, wherein said phospholipids are selected from the list comprising: 1 ,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1 -palmitoyl-2- oleoyl-sn-glycero-3-phosphocholine (POPC), 1 -stearoyl-2-oleoyl-sn-glycero-3- phosphocholine (SOPC), 1 ,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1 ,2- dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1 ,2-distearoyl-sn-glycero-3- phosphocholine (DSPC), 1 ,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1 ,2- dilauroyl-sn-glycero-3-phosphocholine (DLPC), L-a-phosphatidylcholine ((egg)PC), L-a- phosphoethanolamine ((egg)PE), 1 ,2-dioleoyl-sn-glycero-3-phosphatidylglycerol (DOPG), L-a-phosphatidylglycerol ((egg)PG), 1 ,2-dioleoyl-sn-glycero-3-phosphatidic acid (DOPA), L-a-phosphatidic acid ((egg)PA), or combinations thereof. 4. The composition according to claim 2 or 3, wherein the phospholipids are a combination of one or more zwitterionic phospholipids and one or more anionic phospholipids. 5. The composition according to claim 3 or 4, wherein said phospholipids are a combination of DPPC:(egg)PG (1 ,2-dipalmitoyl-sn-glycero-3-phosphocholine; L-a- phosphatidylglycerol), a combination of DPPC:(egg)PA (1 ,2-dipalmitoyl-sn-glycero-3- phosphocholine; L-a-phosphatidic acid), a combination of DOPC:(egg)PG (1 ,2-dioleoyl-sn- glycero-3-phosphocholine; L-a-phosphatidylglycerol) or a combination of DOPC:(egg)PA (1 ,2-dioleoyl-sn-glycero-3-phosphocholine; L-a-phosphatidic acid). 6. The composition according to claim 5, wherein said DPPC:(egg)PG, DPPC:(egg)PA, DOPC:(egg)PG or DOPC:(egg)PA has a ratio of about 85:15. 7. The composition according to any one of claims 1 -6, wherein said SP-B, or said SP-B related protein or peptide, is present at a weight ratio of about 0,1 wt% to about 5,0 wt% with respect to the complete proteolipid composition; more specifically between about 0,4 wt% and about 1 ,6 wt%. 8. The composition according to any one of claims 1 -7, wherein the particle is a dextran nanogel, more in particular a cationic dextran nanogel. 9. The composition according to any one of claims 1 -8, wherein the one or more active agents are selected from the list comprising: a therapeutic agent, a biologically active agent or a diagnostic imaging agent. 10. The composition according to claim 9, wherein the active agent is a nucleic acid, in particular siRNA. 1 1 . The composition according to any one of claims 1 -10, wherein the particle further comprises a targeting ligand, an imaging agent, a fluorescent agent, a PEGylated lipid or a functionalized lipid. 12. A pharmaceutical composition comprising the composition according to any one of claims 1 -1 1 , and a pharmaceutically acceptable excipient, carrier and/or diluent. 13. The composition according to any one of claims 1 -12, for use as a medicament. 14. Use of the composition according to any one of claims 1 -12, for delivering the active agent(s) across cellular membranes in a subject. 15. The use according to claim 14, wherein the composition is administered to the subject by inhalation. 16. Use of a proteolipid composition consisting of surfactant protein B (SP-B) and one or more lipids, for coating particles, in particular dextran nanogels; and wherein said particle is not a cationic liposome.